Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌
Share
Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
By clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌
7/9/2026
Transportation
Release – Seanergy Maritime Announces Pricing of €100 Million Unsecured Corporate Bond trading on Euronext Athens
Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today the pricing of the offering of €100 million of unsecured bonds (the “Bonds”) to investors in Greece. The...
‌
7/9/2026
Health
Release – Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences,...
‌
7/9/2026
Financial Services
Wall Street Is Finally Noticing Small Caps
JPMorgan announced this week that it is building a new investment banking team dedicated entirely to small-cap dealmaking, targeting companies valued between $100 million and $500 million. The team will...
‌
7/9/2026
Health
MAIA Biotechnology (MAIA) – First Data From Phase 2 Part C Trial Shows Data Consistent With Earlier Studies
Data From Part C Announced. MAIA announced data from Part C (Expansion stage) of its Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC). This open-label stage of the trial tests...
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.